Azafaros to Present Phase 3 Nizubaglustat Data for Rare Lysosomal Storage Disorders at WORLDSymposium 2026
核心洞察
Azafaros (搜索) will showcase nizubaglustat's therapeutic potential through five scientific presentations at WORLDSymposium 2026, including long-term Phase II data for GM2 and Niemann-Pick Type C diseases.
The company is currently recruiting patients across the EU, India, and US for two global Phase 3 studies testing nizubaglustat in Niemann-Pick type C disease (搜索) and GM1/GM2 gangliosidoses.
Nizubaglustat has received multiple regulatory designations including Rare Pediatric Disease Designations, Orphan Drug Designations, and Fast Track Designation from the FDA for these rare neurological conditions.
Azafaros (搜索) announced that its lead investigational therapy nizubaglustat will be featured in five scientific presentations at WORLDSymposium 2026, the premier global conference on lysosomal diseases, taking place February 2-6 in San Diego, California. The presentations will highlight the drug's potential in treating rare lysosomal storage disorders (搜索) with neurological involvement.
Phase II Data and Clinical Development Progress
The company will present long-term data from its Phase II RAINBOW study on February 5, showcasing preliminary clinical efficacy and safety data for oral nizubaglustat in late-infantile/juvenile GM2 and Niemann-Pick Type C diseases. According to Azafaros (搜索), the data underscore nizubaglustat's potential as a therapeutic option and reinforce the company's commitment to addressing critical unmet needs in lysosomal storage disorders (搜索).
Nizubaglustat is currently being tested in two global Phase 3 studies for Niemann-Pick type C disease (搜索) and GM1/GM2 gangliosidoses, with recruitment ongoing across multiple sites in the European Union, India, and the United States.
Expanding Research into CLN3 Batten Disease
Additional research will be presented on February 6 during a Rapid Fire session, highlighting nizubaglustat's ability to reinstate pro-neuronal transcriptional programs in human CLN3 (搜索) retinal organoids. This preclinical work positions nizubaglustat as a promising candidate for further development in CLN3 Batten disease (搜索).
Comprehensive Conference Program
Azafaros (搜索) will host a satellite symposium on February 3 entitled "The value of conducting an 18-month placebo-controlled study in Rare Diseases: GM1, GM2 and NPC; the NAVIGATE experience." The symposium will provide an opportunity to engage key opinion leaders, healthcare professionals, and patient advocacy organizations regarding the company's Phase 3 NAVIGATE study design and objectives.
The company will also present three poster presentations covering patient and family perspectives on clinical trial participation, 24-month natural history data from the PRONTO study for GM1 and GM2 gangliosidoses, and details of the Phase III NAVIGATE trial design.
Drug Profile and Regulatory Status
Nizubaglustat is described as a small molecule, orally available and brain penetrant azasugar with a unique dual mode of action. The drug has received extensive regulatory recognition, including Rare Pediatric Disease Designations for GM1 and GM2 gangliosidoses and Niemann-Pick type C from the FDA, along with Orphan Drug Designations for GM1 and GM2 gangliosidosis (搜索) (including Sandhoff and Tay-Sachs diseases) and NPC.
The therapy has also secured Fast Track Designation and IND clearance from the FDA for GM1/GM2 gangliosidoses and NPC. International regulatory support includes Orphan Medicinal Product Designation from the European Medicines Agency for GM1 and GM2 gangliosidoses treatment, and an Innovation Passport from the UK's Medicines and Healthcare Products Regulatory Agency.
Addressing Critical Unmet Medical Needs
GM1 gangliosidosis (搜索) and GM2 gangliosidosis (搜索), which include Tay-Sachs and Sandhoff diseases, are lysosomal storage disorders (搜索) caused by the accumulation of GM1 or GM2 gangliosides in the central nervous system. These conditions result in progressive and severe neurological impairment and premature death, primarily affecting infants and children. Currently, no disease-modifying treatments are available for these conditions.
Niemann-Pick type C disease (搜索) is a progressive, life-limiting neurological lysosomal storage disorder caused by mutations in the NPC1 (搜索) or NPC2 (搜索) genes. The condition leads to aberrant endosomal-lysosomal trafficking and accumulation of various lipids, including gangliosides, in the central nervous system. Disease onset can occur throughout an individual's lifespan, from prenatal life through adulthood.
"We strongly believe nizubaglustat has great potential to become a new therapeutic treatment for lysosomal storage disorders (搜索), in particular Niemann-Pick Type C disease (搜索) and GM1 and GM2 Gangliosidoses, where there is a strong unmet medical need," said Stefano Portolano, Chief Executive Officer at Azafaros (搜索).